Skip to Main Content

This biopharma superlative is a no-brainer: The most noteworthy drug approval of the year goes, hands-down, to the two CAR-T drugs that hit the market earlier this year.

Kymriah, from Novartis (NVS), was approved in late August, with a price tag set at $475,000. And Yescarta, developed by Kite Pharma and acquired by Gilead Sciences (GILD), was approved in October, with a $373,000 set price. Both work with just a single infusion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.